Article
Cardiac & Cardiovascular Systems
Anurag Mehta, Nestor Vasquez, Colby R. Ayers, Jaideep Patel, Ananya Hooda, Amit Khera, Roger S. Blumenthal, Michael D. Shapiro, Carlos J. Rodriguez, Michael Y. Tsai, Laurence S. Sperling, Salim S. Virani, Michael J. Blaha, Parag H. Joshi
Summary: Elevated lipoprotein(a) and coronary artery calcium are independently associated with ASCVD risk, and may be concurrently useful in guiding primary prevention therapy decisions, as demonstrated in the MESA and DHS cohorts.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2022)
Review
Medicine, General & Internal
Harpreet S. Bhatia, Michael J. Wilkinson
Summary: This article provides a detailed overview of the evidence supporting Lp(a) as a causal risk factor for ASCVD and AS/CAVD, and discusses approaches for managing Lp(a)-associated risk.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Medicine, Research & Experimental
Shiyue Wang, Li Zha, Jian Chen, Dongjie Du, Danyang Liu, Ming Zhong, Rongfang Shang, Dongxue Sun, Chang Sun, Enze Jin
Summary: This study found a causal relationship between lipoprotein(a) (Lp(a)) and coronary heart disease, aortic aneurysm, and large artery atherosclerosis stroke. However, no causal association was found with atrial fibrillation, heart failure, ischemic stroke, small vessel stroke, lacunar stroke, secondary hypertension, or pulmonary embolism.
EUROPEAN JOURNAL OF MEDICAL RESEARCH
(2022)
Article
Cardiac & Cardiovascular Systems
Benjamin Nilsson Wadstrom, Anders Berg Wulff, Kasper Monsted Pedersen, Gorm Boje Jensen, Borge Gronne Nordestgaard
Summary: The study found that elevated remnant cholesterol levels are associated with an increased risk of peripheral artery disease, higher than the risk increase for myocardial infarction and ischemic stroke.
EUROPEAN HEART JOURNAL
(2022)
Article
Cardiac & Cardiovascular Systems
Paul Welsh, Claire Welsh, Carlos A. Celis-Morales, Rosemary Brown, Frederick K. Ho, Lyn D. Ferguson, Patrick B. Mark, James Lewsey, Stuart R. Gray, Donald M. Lyall, Jason M. R. Gill, Jill P. Pell, James A. de Lemos, Peter Willeit, Naveed Sattar
Summary: This study investigates the population attributable fraction due to elevated lipoprotein (a) (Lp(a)) and the utility of measuring Lp(a) in cardiovascular disease (CVD) risk prediction. The results show that Lp(a) is associated with CVD, fatal CVD, coronary heart disease (CHD), peripheral vascular disease (PVD), and aortic stenosis. Incorporating Lp(a) into prediction models improves risk prediction in the primary prevention group. The study also suggests that reducing Lp(a) levels may decrease CVD and CHD risk.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
(2022)
Article
Hematology
Jing-Wei Gao, Si You, Zhao-Yu Liu, Qing-Yun Hao, Jing-Feng Wang, Dominique A. Vuitton, Shao-Ling Zhang, Pin-Ming Liu
Summary: The study found that metabolically healthy obesity (MHO) is associated with an increased risk of coronary artery calcium (CAC) progression and subsequent cardiovascular disease events. However, MHO individuals have a lower risk of cardiovascular disease compared to metabolically healthy individuals with normal weight.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
(2022)
Article
Multidisciplinary Sciences
C. J. MacDonald, A. L. Madika, G. Severi, A. Fournier, M. C. Boutron-Ruault
Summary: The study found that non-O blood groups, particularly the A group, are associated with an increased risk of dyslipidaemia. Current smokers have a 30% higher risk of dyslipidaemia compared to never-smokers. These results could be useful for personalized approaches to preventing cardiovascular risk factors.
SCIENTIFIC REPORTS
(2021)
Review
Biochemistry & Molecular Biology
Harold Superko, Brenda Garrett
Summary: Despite statin use and LDL-C reduction, residual cardiovascular disease event risk remains. Abnormal lipoprotein size and density distribution, known as lipoprotein heterogeneity, contributes to this residual risk. Recent clinical trial evidence reinforces the importance of LDL heterogeneity measurement and its impact on CHD risk prediction and outcomes.
Article
Cardiac & Cardiovascular Systems
Katarzyna Bergmann, Anna Stefanska, Magdalena Krintus, Grazyna Sypniewska
Summary: This study evaluated the association between Lp(a) and lipid biomarkers of cardiovascular risk, finding that women younger than 40 with low LDL-C may be at increased cardiovascular risk associated with elevated Lp(a) and apolipoprotein B levels. The inclusion of Lp(a) and apoB in routine lipid testing may improve the prediction of cardiovascular risk in primary prevention.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
(2023)
Review
Medicine, General & Internal
Pyotr Telyuk, David Austin, Ahai Luvai, Azfar Zaman
Summary: After the discovery of Lp(a) molecule in 1963, there are still many physiological and pathological properties of this particle that need to be fully understood. Several studies have shown a correlation between elevated Lp(a) levels and the incidence of cardiovascular disease, as well as the progression of calcific aortic stenosis. The interest in Lp(a) has increased due to emerging therapies that can specifically reduce its concentration, leading to updates in international guidelines advocating Lp(a) testing in specific population groups.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Hematology
Gissette Reyes-Soffer, Henry N. Ginsberg, Lars Berglund, P. Barton Duell, Sean P. Heffron, Pia R. Kamstrup, Donald M. Lloyd-Jones, Santica M. Marcovina, Calvin Yeang, Marlys L. Koschinsky
Summary: High levels of Lp(a) are an independent and causal risk factor for atherosclerotic cardiovascular diseases. Genetic factors determine 70% to 90% of interindividual heterogeneity in Lp(a) levels. There is a lack of standardized assays, diagnostic guidelines, and targeted treatments for lowering Lp(a). Understanding the genetic and biological basis for variation in Lp(a) levels in different populations is crucial.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
(2022)
Article
Medicine, Research & Experimental
Georgia Anastasiou, Eftihia Sakka, Efi Blathra, Anna Kalivi, Moses Elisaf, George Liamis, Evangelos Liberopoulos
Summary: This retrospective study analyzed patients with Lp(a) levels >= 30 mg/dL at the University of Ioannina Hospital Lipid Clinic, revealing a significant proportion of patients with cardiovascular diseases, familial hypercholesterolemia, and positive family history of early ASCVD. Lipid-lowering therapy was effective in reducing LDL-C levels in different patient groups.
ARCHIVES OF MEDICAL RESEARCH
(2021)
Article
Medicine, General & Internal
In Sun Ryou, Ju Young Kim, Hwa Yeon Park, Sohee Oh, Sehun Kim, Hwa Jung Kim
Summary: The study found that the risk of MACE incidence decreased in statin users, but increased for low-risk statin users, with no significant relationship identified for intermediate and borderline risk groups. The risk of MACE incidence decreased only in the high CVD risk group among statin users.
FRONTIERS IN MEDICINE
(2022)
Article
Cardiac & Cardiovascular Systems
Harpreet S. Bhatia, Rishi Rikhi, Tara S. Allen, Calvin Yeang, Weihua Guan, Parveen K. Garg, Michael Y. Tsai, Michael H. Criqui, Michael D. Shapiro, Sotirios Tsimikas
Summary: This study evaluated the performance of the Pooled Cohort Equations (PCE) in predicting 10-year event rates in individuals with elevated lipoprotein(a) (Lp(a)), and investigated whether the addition of Lp(a) improves risk prediction. The results showed that the PCE accurately predicted 10-year event rates for individuals with elevated Lp(a), and elevated Lp(a) was associated with increased risk of cardiovascular disease (CVD). Adding Lp(a) to the PCE improved risk prediction, especially for low-risk individuals. These findings support the use of Lp(a) testing for risk assessment.
Review
Biochemistry & Molecular Biology
Simonetta Genovesi, Marco Giussani, Giulia Lieti, Antonina Orlando, Ilenia Patti, Gianfranco Parati
Summary: Lp(a) is composed of apo(a) and an LDL-like particle, and its proportion is genetically determined. It is associated with cardiovascular disease and calcific aortic valve stenosis. Research on Lp(a) in children and adolescents is limited, but this article reviews its changes during growth, correlation with parental values, and relationship with family history of cardiovascular disease. Understanding these points is crucial for defining cardiovascular risk in children and planning early prevention programs.
Review
Food Science & Technology
Mamali Das, Kasi Pandima Devi, Tarun Belwal, Hari Prasad Devkota, Devesh Tewari, Adeleh Sahebnasagh, Seyed Fazel Nabavi, Hamid Reza Khayat Kashani, Mahsa Rasekhian, Suowen Xu, Mehran Amirizadeh, Kiumarth Amini, Maciej Banach, Jianbo Xiao, Safieh Aghaabdollahian, Seyed Mohammad Nabavi
Summary: Vascular diseases are caused by abnormal endothelial response, resulting in atherosclerosis, hypercholesterolemia, etc. Polyphenols have antioxidative, anti-inflammatory, and anti-hypertensive properties, beneficial for preventing endothelial dysfunction.
CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION
(2023)
Article
Medicine, General & Internal
Emili Vela, Montse Cleries, Usama Bilal, Maciej Banach, John McEvoy, Martin Bodtker Mortensen, Michael Blaha, Khurram Nasir, Josep Comin-Colet, Josepa Mauri, Miguel Cainzos-Achirica
Summary: This study investigated the burden of cardiovascular diseases among European-born immigrants living in Catalonia, a low-risk region. The results showed that residents from high-risk countries were more likely to develop coronary heart disease and newly diagnosed risk factors. Therefore, low-risk countries should consider tailored prevention efforts and early screening to better address the health needs of men and women from higher-risk countries.
ARCHIVES OF MEDICAL SCIENCE
(2023)
Article
Medicine, General & Internal
Bojan Mitrovic, Zoran M. Gluvic, Milan Obradovic, Maja Radunovic, Manfredi Rizzo, Maciej Banach, Esma R. Isenovic
Summary: Non-alcoholic fatty liver disease (NAFLD), metabolic syndrome (MetS), and type 2 diabetes (T2DM) are highly prevalent metabolic disorders with significant impacts on global public health. MetS is a complex condition characterized by glucose intolerance, insulin resistance, dyslipidemia, inflammation, and hypertension. NAFLD, recognized as a hepatic manifestation of MetS, is often associated with T2DM. This review examines the underlying connections between these diseases and the risks associated with their co-occurrence.
ARCHIVES OF MEDICAL SCIENCE
(2023)
Review
Medicine, General & Internal
Pierre Sabouret, Luigi Spadafora, David Fischman, Waqas Ullah, Michel Zeitouni, Martha Gulati, Salvatore De Rosa, Michael P. Savage, Juan Pablo Costabel, Maciej Banach, Giuseppe Biondi-Zoccai, Mattia Galli
Summary: Dual antiplatelet therapy (DAPT) is the standard treatment for ACS or CCS patients undergoing PCI. The use of more potent P2Y12 inhibitors, such as prasugrel and ticagrelor, has shown to reduce ischemic events compared to clopidogrel after ACS. However, prolonged and potent antiplatelet therapy is associated with increased bleeding. A new strategy called de-escalation, involving less intense antithrombotic therapy after a short course of standard DAPT, has been shown to reduce bleeding without compromising ischemic events.
EUROPEAN JOURNAL OF INTERNAL MEDICINE
(2023)
Review
Endocrinology & Metabolism
Djordje S. Popovic, Nikolaos Papanas, Theocharis Koufakis, Kalliopi Kotsa, Wael Al Mahmeed, Khalid Al-Rasadi, Kamila Al-Alawi, Maciej Banach, Yajnavalka Banerjee, Antonio Ceriello, Mustafa Cesur, Francesco Cosentino, Alberto Firenze, Massimo Galia, Su-Yen Goh, Andrej Janez, Sanjay Kalra, Peter Kempler, Nitin Kapoor, Nader Lessan, Paulo Lotufo, Ali A. Rizvi, Amirhossein Sahebkar, Raul D. Santos, Anca Pantea Stoian, Peter P. Toth, Vijay Viswanathan, Manfredi Rizzo
Summary: There is bidirectional relation between COVID-19 and T2DM and effective ways are needed to counter the glucometabolic disturbances during acute COVID-19 illness in T2DM patients. Novel antidiabetic medications are considered candidate drugs for tackling these disturbances.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
(2023)
Review
Endocrinology & Metabolism
Martyna Fronczek, Tadeusz Osadnik, Maciej Banach
Summary: The purpose of this study was to review recent publications and examine the relationship between genetic variants in the vitamin D receptor (VDR) gene and type 2 diabetes, metabolic syndrome, overweight, and obesity. Recent studies have focused on genetic variants in both coding and noncoding regions of the VDR gene, which may affect VDR expression or functionality. However, the data collected in recent months still do not provide a clear answer regarding the direct impact of VDR genetic variants on these metabolic disorders.
CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE
(2023)
Review
Cardiac & Cardiovascular Systems
Ali Mahmoudi, Alexandra E. Butler, Maciej Banach, Tannaz Jamialahmadi, Amirhossein Sahebkarh
Summary: In this study, a virtual screening approach was used to identify a potent small-molecule PCSK9 inhibitor. Through pharmacophore screening and molecular docking, ZINC000051951669 was found to have the highest binding affinity to the PCSK9 protein. This compound shows potential as a novel therapeutic candidate for further study.
CURRENT PROBLEMS IN CARDIOLOGY
(2023)
Review
Cardiac & Cardiovascular Systems
Maciej Banach, Peter E. Penson, Michel Farnier, Zlatko Fras, Gustavs Latkovskis, Ulrich Laufs, Francesco Paneni, Paolo Parini, Matteo Pirro, Zeljko Reiner, Michal Vrablik, Carlos Escobar
Summary: Cardiovascular disease (CVD) is a chronic non-communicable disease and the leading cause of disability and mortality worldwide. The current lipid-lowering treatments need improvement, and bempedoic acid, as a new approach to reduce lipid levels, has the potential to lower the risk of CVD.
PROGRESS IN CARDIOVASCULAR DISEASES
(2023)
Review
Chemistry, Medicinal
Niki Katsiki, Michal Vrablik, Maciej Banach, Ioanna Gouni-Berthold
Summary: Dyslipidemia treatment is crucial for reducing the risk of ASCVD, the leading cause of death worldwide. PCSK9 inhibitors, including inclisiran, have emerged as a novel category of lipid-lowering drugs. Inclisiran, a siRNA against PCSK9, has been approved for treating hypercholesterolemia and offers a long-lasting LDL-C-lowering effect with just two doses per year. The ORION/VICTORION clinical trial program investigates the impact of inclisiran on atherogenic lipoproteins and major cardiac events in different patient populations.
Editorial Material
Cardiac & Cardiovascular Systems
Fotios Barkas, Kausik K. Ray
EUROPEAN HEART JOURNAL
(2023)
Editorial Material
Cardiac & Cardiovascular Systems
Stanislaw Surma, Amirhossein Sahebkar, Maciej Banach
EUROPEAN HEART JOURNAL
(2023)
Editorial Material
Cardiac & Cardiovascular Systems
Pierre Sabouret, Fiona Ecarnot, Salvatore De Rosa, Kausik K. Ray
EUROPEAN HEART JOURNAL
(2023)
Letter
Cardiac & Cardiovascular Systems
C. Vlachopoulos, D. Massia, G. Kochiadakis, G. Kolovou, S. Patsilinakos, I. Bridges, M. Sibartie, N. N. Dhalwani, E. Liberopoulos, K. K. Ray
HELLENIC JOURNAL OF CARDIOLOGY
(2023)
Article
Medicine, General & Internal
Katarzyna Gryglewska-Wawrzak, Agata Sakowicz, Maciej Banach, Ibadete Bytyci, Agata Bielecka-Dabrowa
Summary: The study investigated risk factors and the utility of spiroergometry parameters for diagnosing patients with long COVID symptoms. Patients with long COVID symptoms exhibited different clinical, laboratory, and spirometry characteristics compared to the control group. The FEV1/FVC% ratio was found to be the most powerful predictor of long COVID symptoms.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Medicine, General & Internal
Francesco Perone, Marco Bernardi, Alban Redheuil, Dario Mafrica, Edoardo Conte, Luigi Spadafora, Fiona Ecarnot, Lale Tokgozoglu, Carlos G. Santos-Gallego, Sergio Emanuel Kaiser, Federica Fogacci, Annabelle Sabouret, Deepak L. Bhatt, Francesco Paneni, Maciej Banach, Raul Santos, Giuseppe Biondi Zoccai, Kausik K. Ray, Pierre Sabouret
Summary: Optimal risk assessment for primary prevention is challenging and there are major discrepancies between guidelines and practice. Cardiovascular imaging plays a crucial role in categorizing individuals and enabling precise therapeutic strategies. Further research is needed to define individual residual risk and intensify treatment in high-risk subgroups.
JOURNAL OF CLINICAL MEDICINE
(2023)